Who are MMRVNS's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): live attenuated Japanese encephalitis vaccine, Pentavalent rotavirus vaccine, BCG Solution, Bacille Calmette-Guerin, Yellow fever vaccine, Institut Pasteur, Measles, mumps, rubella vaccine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mmrvns.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MMRVNS — Competitive Intelligence Brief

MMRVNS (MMRVNS) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: live attenuated vaccine. Area: Infectious Disease.

phase 3 live attenuated vaccine Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MMRVNS (MMRVNS) — GlaxoSmithKline. MMRV vaccine is a live attenuated vaccine that stimulates the body's immune response to protect against measles, mumps, rubella, and varicella.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
MMRVNS TARGET	MMRVNS	GlaxoSmithKline	phase 3	live attenuated vaccine
live attenuated Japanese encephalitis vaccine	live attenuated Japanese encephalitis vaccine	Chinese Academy of Medical Sciences	marketed	Live attenuated vaccine
Pentavalent rotavirus vaccine	Pentavalent rotavirus vaccine	Sanofi Pasteur, a Sanofi Company	marketed	Live attenuated vaccine
BCG Solution	BCG Solution	Alliance for Clinical Trials in Oncology	marketed	Live attenuated vaccine / Immunotherapy
Bacille Calmette-Guerin	Bacille Calmette-Guerin	Urological Oncology Council of Northern Tokyo	marketed	Live attenuated vaccine / Immunotherapeutic agent
Yellow fever vaccine, Institut Pasteur	Yellow fever vaccine, Institut Pasteur	University of Oxford	marketed	Live attenuated vaccine
Measles, mumps, rubella vaccine	Measles, mumps, rubella vaccine	PATH	marketed	Live attenuated vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (live attenuated vaccine class)

GlaxoSmithKline · 2 drugs in this class
Centers for Disease Control and Prevention · 1 drug in this class
MedImmune LLC · 1 drug in this class
Sanofi Pasteur, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MMRVNS — Competitive Intelligence Brief. https://druglandscape.com/ci/mmrvns. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab